Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treat-and-extend intravitreal aflibercept for macular edema secondary to central retinal vein occlusion
2014-003193-17Phase 4Completed
- Sponsor
- Bayer
- Start
- May 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in central retinal vein occlusion with macular edema and central retinal vein occlusion (CRVO), sponsored by Bayer. Primary endpoint: Proportion of subjects gaining at least 15 letters in best corrected visual acuity. Started May 2016; status: completed.
02
Drugs
aflibercept
03
Conditions
central retinal vein occlusion with macular edemacentral retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on 2014-003193-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003193-17.